Trial Profile
Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Methotrexate
- Indications Axial spondyloarthritis; Spondylarthritis
- Focus Proof of concept; Therapeutic Use
- Acronyms CRESPA
- 06 Oct 2022 Results of post-hoc analysis assessing the reliability, validity, and sensitivity to change of a novel MRI scoring system in early peripheral spondylarthritis, published in the Rheumatology.
- 20 Jan 2021 Results of CRESPA-Extension protocol (n=31) published in the Rheumatology
- 28 Oct 2020 Results assessing axial involvement on MRI in early peripheral spondyloarthritis, published in the Annals of the Rheumatic Diseases